RADXNasdaqPharmaceutical PreparationsFiscal year ends June 30Also trades as RDPTF

Radiopharm Theranostics Ltd

Financials through fiscal 2026, year ended Jun 30, 2026Last filing: 20-F on Sep 30, 2026

$0.96−0.07 (-6.50%)

Close on Oct 19, 2026

Market cap: –
P/E (TTM): –
Dividend yield: –

Radiopharm Theranostics Ltd income statement

AnnualQuarterlyTTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2026 2026-06-30	FY 2025 2025-06-30	FY 2024 2024-06-30	FY 2023 2023-06-30
Revenue	2.77	3.63	0.30	0.29
Cost of Revenue	2.50	3.59	–	–
Gross Profit	0.26	0.04	0.30	0.29
Research & Development	50	28	23	23
Operating Income	-57	-38	-47	-34
Interest Expense	0.11	0.07	0.64	0.09
Pretax Income	-57	-38	-48	-35
Income Tax Expense	0.05	0.10	0.10	0.04
Net Income incl. Noncontrolling Interests	-57	-38	-48	-35
EPS (Basic)(per share)	-1.79	-1.76	-12.41	-11.32
EPS (Diluted)(per share)	-1.79	-1.76	-12.41	-11.32
Shares Outstanding (Basic, Weighted)(shares)	3,073	2,081	386	306
Shares Outstanding (Diluted, Weighted)(shares)	3,073	2,081	386	306
EBITDA	-54	-36	-44	-31

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY2026

Gross margin: 9.5%
Operating margin: -2051.5%
Net margin: –
Return on equity, FY2026: –

Financial strength

Current ratio: 1.16
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 21.9%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –